SCHEMBL14907889

SCHEMBL14907889

COC(=O)CSc1nnc(-c2cccc(C)c2)[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
GRK6 P43250 1/20 0.46
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALOX12 P18054 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 3/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 1/20 0.43
TP53 P04637 1/20 0.43
PIN1 Q13526 1/20 0.42
THRB P10828 1/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 1/20 0.41
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6405045 0.86 GRK6 (0.60) ALDH1A1GRK6HSD17B10KMT2AMAPT
SCHEMBL16171163 0.86 GRK6 (0.48) POLBSMN1; SMN2ALDH1A1LMNAGRK6
SCHEMBL6411187 0.85 GRK6 (0.47) POLBSMN1; SMN2ALDH1A1GRK6MAPT
SCHEMBL6405968 0.82 HDAC6 (0.52) SMN1; SMN2ALDH1A1LMNAGRK6GAA
SCHEMBL6406023 0.80 NPC1 (0.47) POLBSMN1; SMN2ALDH1A1LMNAGAA
SCHEMBL6410220 0.80 MAPK14 (0.55) POLBSMN1; SMN2ALDH1A1LMNAGAA
SCHEMBL23527219 0.79 LMNA (0.61) ALDH1A1LMNAGRK6GAAL3MBTL1
SCHEMBL31140787 0.79 LMNA (0.61) ALDH1A1LMNAGRK6GAAL3MBTL1
SCHEMBL14907872 0.79 MAPT (0.57) LMNAGRK6GAAL3MBTL1MAPT
SCHEMBL16171184 0.77 GRK6 (0.53) ALDH1A1GRK6HSD17B10MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3134390-B1 SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES MAYO FOUND MEDICAL EDUCATION & RES (US) 2020-02-26 EP disclosed
US-10252984-B2 Inhibiting G protein coupled receptor 6 kinase polypeptides MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2019-04-09 US disclosed
US-20170050939-A1 SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2017-02-23 US disclosed
WO-2015164415-A1 SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2015-10-29 WO disclosed
US-20140309185-A1 Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2014-10-16 US disclosed
US-20140309185-A1 Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2014-10-16 US disclosed
WO-2013063458-A2 INHIBITING G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050939-A1 SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES GRK6, GRK2, GRK3 POLB 4006/4885SMN1; SMN2 4578/4885ALDH1A1 4745/4885
US-20140309185-A1 Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides GRK6, GRK2, GRK3 POLB 3654/4885SMN1; SMN2 4298/4885ALDH1A1 4731/4885
US-10252984-B2 Inhibiting G protein coupled receptor 6 kinase polypeptides GRK6, GRK2, GRK3 POLB 3654/4885SMN1; SMN2 4298/4885ALDH1A1 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.